CA-NETAPP
5.3.2024 14:02:00 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced new capabilities that maximize the potential of generative artificial intelligence (Gen AI) projects and build competitive advantage for users. Customers can now take their AI projects to the next level by combining NetApp’s intelligent data infrastructure with high-performance compute, networking and software from NVIDIA.
Gen AI has captured global attention for its potential to automate tedious tasks, uncover new insights, and drive product innovation. Nearly three out of four companies are already using Gen AI, according to the NetApp 2023 Data Complexity report. To unlock the potential of Gen AI, organizations need secure, high-performance access to data spread across complex hybrid and multicloud environments. NetApp has a long and successful history of expertise in supporting AI with solutions that deliver management simplicity anywhere data lives, provide high performance without requiring new infrastructure silos, and supply trusted, secure data to drive responsible AI.
“NetApp is the intelligent data infrastructure company, with solutions optimized to maximize the potential of our customers’ AI investments,” said Arunkumar Gururajan, Vice President of Data Science & Research at NetApp. “Our unique approach to AI gives customers complete access and control over their data throughout the data pipeline, moving seamlessly between their public cloud and on-premises environments. By tiering object storage for each phase of the AI process, our customers can optimize both performance and costs exactly where they need them. Our unified approach delivers the performance, productivity, and protection customers need to quickly innovate with AI.”
To support companies leveraging Gen AI to improve their operations and strategic decision-making, NetApp released updates to its intelligent data infrastructure capabilities including:
- NetApp AIPod™ is NetApp's AI-optimized converged infrastructure for organizations’ highest priority AI projects, including training and inferencing. NetApp AIPod powered by NVIDIA DGX is now a certified NVIDIA DGX BasePOD solution using NVIDIA DGX H100 systems integrated with NetApp AFF C-Series affordable capacity flash systems to drive a new level of cost/performance while optimizing rack space and sustainability. NetApp AIPod powered by NVIDIA DGX also continues to support NVIDIA DGX A100 systems.
- New FlexPod for AI reference architectures extend the leading converged infrastructure solution from NetApp and Cisco. FlexPod for AI now supports the NVIDIA AI Enterprise software platform. FlexPod for AI can now be extended to leverage RedHat OpenShift and SuSE Rancher. New scaling and benchmarking have been added to support increasingly GPU-intensive applications. Customers can use these new FlexPod solutions as an end-to-end blueprint to efficiently design, deploy, and operate the FlexPod platform for AI use cases.
- NetApp is now validated for NVIDIA OVX systems. NetApp storage combined with NVIDIA OVX computing systems can help streamline enterprise AI deployments, including model fine-tuning and inference workloads. Powered by NVIDIA L40S GPUs, validated NVIDIA OVX solutions are available from leading server vendors and include NVIDIA AI Enterprise software along with NVIDIA Quantum-2 InfiniBand or NVIDIA Spectrum-X Ethernet, and NVIDIA BlueField-3 DPUs. NetApp is one of the first partners to complete this new storage validation for NVIDIA OVX.
To further enhance its AI leadership, NetApp also is announcing revolutionary new cyber-resilience capabilities including one of the first uses of AI/ML embedded in storage to fight ransomware. The new Autonomous Ransomware Protection with AI (ARP/AI) will provide the next generation of machine learning in ONTAP, giving the increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats.
“AI powers mission-critical use cases in every industry, from healthcare to manufacturing to financial services,” said Tony Paikeday, Senior Director of AI Systems at NVIDIA. “NetApp AIPod certified for NVIDIA DGX BasePOD provides a powerful reference architecture that helps enterprises eliminate design complexity, reduce deployment time frames, and simplify ongoing operations.”
“GenAI has massive potential to help organizations harness their data to uncover business insights and improve operational efficiency,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp has continuously adapted to deliver the services and solutions customers need to effectively manage their data pipelines. These updates further illustrate NetApp’s willingness to evolve and bring innovations to customers that unlock the full potential of AI.”
NetApp delivers a unified approach to infrastructure and data management that eliminates data silos, brings enhanced performance and trusted data protection to customers’ AI turnkey solutions, and helps customers accelerate the time to results for their AI projects.
To learn more about the NetApp offerings to support Gen AI, visit: https://www.netapp.com/artificial-intelligence/
Additional Resources
- Your Data, Your AI, Anywhere: Introducing the NetApp AIPod Now Certified on NVIDIA's DGX H100
- FlexPod: Where Converged Meets Cloud
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305729049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
